Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

被引：170

作者：

Gyorffy, Balazs ^{[1
,2
,3
]}

Bottai, Giulia ^{[4
]}

Fleischer, Thomas ^{[5
,6
]}

Munkacsy, Gyongyi ^{[1
]}

Budczies, Jan ^{[7
]}

Paladini, Laura ^{[4
]}

Borresen-Dale, Anne-Lise ^{[5
,6
]}

Kristensen, Vessela N. ^{[5
,6
,8
,9
]}

Santarpia, Libero ^{[4
]}

机构：

[1] MTA TTK Lendulet Canc Biomarker Res Grp, Budapest, Hungary

[2] Semmelweis Univ, Dept Pediat 2, H-1085 Budapest, Hungary

[3] MTA SE Pediat & Nephrol Res Grp, Budapest, Hungary

[4] IRCCS Clin & Res Inst Humanitas, Oncol Expt Therapeut Unit, I-20089 Rozzano Milan, Italy

[5] OUS Radiumhosp, Inst Canc Res, Dept Genet, Oslo, Norway

[6] Univ Oslo, Fac Med, Inst Clin Med, KG Jebsen Ctr Breast Canc Res, N-0316 Oslo, Norway

[7] Charite, Inst Pathol, Campus Charite Mitte, D-13353 Berlin, Germany

[8] Akershus Univ Hosp, Div Med, Dept Clin Mol Biol, Lorenskog, Norway

[9] Akershus Univ Hosp, Lab Sci EpiGen, Div Med, Lorenskog, Norway

来源：

INTERNATIONAL JOURNAL OF CANCER | 2016年 / 138卷 / 01期

关键词：

breast cancer subtypes; DNA methylation biomarkers; gene expression; immune genes; prognosis; TUMOR-INFILTRATING LYMPHOCYTES; HORMONE-RECEPTOR STATUS; MOLECULAR SUBTYPES; PROFILES; REVEALS; SFRP1; CHEMOTHERAPY; RECURRENCE; PATHWAY; RISK;

D O I：

10.1002/ijc.29684

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

DNA methylation has a substantial impact on gene expression, affecting the prognosis of breast cancer (BC) patients dependent on molecular subtypes. In this study, we investigated the prognostic relevance of the expression of genes reported as aberrantly methylated, and the link between gene expression and DNA methylation in BC subtypes. The prognostic value of the expression of 144 aberrantly methylated genes was evaluated in ER+/HER2-, HER2+, and ER-/HER2- molecular BC subtypes, in a meta-analysis of two large transcriptomic cohorts of BC patients (n=1,938 and n=1,640). The correlation between gene expression and DNA methylation in distinct gene regions was also investigated in an independent dataset of 104 BCs. Survival and Pearson correlation analyses were computed for each gene separately. The expression of 48 genes was significantly associated with BC prognosis (p<0.05), and 32 of these prognostic genes exhibited a direct expression-methylation correlation. The expression of several immune-related genes, including CD3D and HLA-A, was associated with both relapse-free survival (HR=0.42, p=3.5E-06; HR=0.35, p=1.7E-08) and overall survival (HR=0.50, p=5.5E-04; HR=0.68, p=4.5E-02) in ER-/HER2- BCs. On the overall, the distribution of both positive and negative expression-methylation correlation in distinct gene regions have different effects on gene expression and prognosis in BC subtypes. This large-scale meta-analysis allowed the identification of several genes consistently associated with prognosis, whose DNA methylation could represent a promising biomarker for prognostication and clinical stratification of patients with distinct BC subtypes. What's new? DNA methylation profiles may play an important role in the development and progression of breast cancer (BC) subtypes, but the prognostic value of aberrantly methylated biomarkers in distinct subtypes and the role of DNA methylation in distinct gene regions remain controversial. This study assesses the prognostic impact of the expression of aberrantly methylated genes and expression-methylation correlations in BC subtypes. Key methylated prognostic genes were identified, including immune-related genes, particularly in ER-/HER2- tumors. DNA methylation in specific gene regions differentially affects gene expression, supporting the importance of epigenetic biomarkers for prognostication and clinical stratification of patients with distinct BC subtypes.

引用

页码：87 / 97

页数：11

共 46 条

[1]

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 [J].

Adams, Sylvia ;

Gray, Robert J. ;

Demaria, Sandra ;

Goldstein, Lori ;

Perez, Edith A. ;

Shulman, Lawrence N. ;

Martino, Silvana ;

Wang, Molin ;

Jones, Vicky E. ;

Saphner, Thomas J. ;

Wolff, Antonio C. ;

Wood, William C. ;

Davidson, Nancy E. ;

Sledge, George W. ;

Sparano, Joseph A. ;

Badve, Sunil S. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2959-+

[2]

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer [J].

Andre, Fabrice ;

Dieci, Maria V. ;

Dubsky, Peter ;

Sotiriou, Christos ;

Curigliano, Giuseppe ;

Denkert, Carsten ;

Loi, Sherene .

CLINICAL CANCER RESEARCH, 2013, 19 (01) :28-33

[3]

Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? [J].

Baylin, SB ;

Ohm, JE .

NATURE REVIEWS CANCER, 2006, 6 (02) :107-116

[4]

DNA methylation epigenotypes in breast cancer molecular subtypes [J].

Bediaga, Naiara G. ;

Acha-Sagredo, Amelia ;

Guerra, Isabel ;

Viguri, Amparo ;

Albaina, Carmen ;

Ruiz Diaz, Irune ;

Rezola, Ricardo ;

Jesus Alberdi, Maria ;

Dopazo, Joaquin ;

Montaner, David ;

de Renobales, Mertxe ;

Fernandez, Agustin F. ;

Field, John K. ;

Fraga, Mario F. ;

Liloglou, Triantafillos ;

de Pancorbo, Marian M. .

BREAST CANCER RESEARCH, 2010, 12 (05)

[5]

The role of classical and non-classical HLA class I antigens in human tumors [J].

Bukur, Juergen ;

Jasinski, Simon ;

Seliger, Barbara .

SEMINARS IN CANCER BIOLOGY, 2012, 22 (04) :350-358

[6]

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups [J].

Curtis, Christina ;

Shah, Sohrab P. ;

Chin, Suet-Feung ;

Turashvili, Gulisa ;

Rueda, Oscar M. ;

Dunning, Mark J. ;

Speed, Doug ;

Lynch, Andy G. ;

Samarajiwa, Shamith ;

Yuan, Yinyin ;

Graef, Stefan ;

Ha, Gavin ;

Haffari, Gholamreza ;

Bashashati, Ali ;

Russell, Roslin ;

McKinney, Steven ;

Langerod, Anita ;

Green, Andrew ;

Provenzano, Elena ;

Wishart, Gordon ;

Pinder, Sarah ;

Watson, Peter ;

Markowetz, Florian ;

Murphy, Leigh ;

Ellis, Ian ;

Purushotham, Arnie ;

Borresen-Dale, Anne-Lise ;

Brenton, James D. ;

Tavare, Simon ;

Caldas, Carlos ;

Aparicio, Samuel .

NATURE, 2012, 486 (7403) :346-352

[7]

DNA methylation profiling reveals a predominant immune component in breast cancers [J].

Dedeurwaerder, Sarah ;

Desmedt, Christine ;

Calonne, Emilie ;

Singhal, Sandeep K. ;

Haibe-Kains, Benjamin ;

Defrance, Matthieu ;

Michiels, Stefan ;

Volkmar, Michael ;

Deplus, Rachel ;

Luciani, Judith ;

Lallemand, Francoise ;

Larsimont, Denis ;

Toussaint, Jerome ;

Haussy, Sandy ;

Rothe, Francoise ;

Rouas, Ghizlane ;

Metzger, Otto ;

Majjaj, Samira ;

Saini, Kamal ;

Putmans, Pascale ;

Hames, Gerald ;

van Baren, Nicolas ;

Coulie, Pierre G. ;

Piccart, Martine ;

Sotiriou, Christos ;

Fuks, Francois .

EMBO MOLECULAR MEDICINE, 2011, 3 (12) :726-741

[8]

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].

Denkert, Carsten ;

Loibl, Sibylle ;

Noske, Aurelia ;

Roller, Marc ;

Mueller, Berit Maria ;

Komor, Martina ;

Budczies, Jan ;

Darb-Esfahani, Silvia ;

Kronenwett, Ralf ;

Hanusch, Claus ;

von Toerne, Christian ;

Weichert, Wilko ;

Engels, Knut ;

Solbach, Christine ;

Schrader, Iris ;

Dietel, Manfred ;

von Minckwitz, Gunter .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113

[9]

beadarray:: R classes and methods for Illumina bead-based data [J].

Dunning, Mark J. ;

Smith, Mike L. ;

Ritchie, Matthew E. ;

Tavare, Simon .

BIOINFORMATICS, 2007, 23 (16) :2183-2184

[10]

miRNA-mRNA Integrated Analysis Reveals Roles for miRNAs in Primary Breast Tumors [J].

Enerly, Espen ;

Steinfeld, Israel ;

Kleivi, Kristine ;

Leivonen, Suvi-Katri ;

Aure, Miriam R. ;

Russnes, Hege G. ;

Ronneberg, Jo Anders ;

Johnsen, Hilde ;

Navon, Roy ;

Rodland, Einar ;

Makela, Rami ;

Naume, Bjorn ;

Perala, Merja ;

Kallioniemi, Olli ;

Kristensen, Vessela N. ;

Yakhini, Zohar ;

Borresen-Dale, Anne-Lise .

PLOS ONE, 2011, 6 (02)

← 1 2 3 4 5 →